Serina Therapeutics (SER) Price & Analysis

Compare

213 Followers

SER Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.81 - $10.28

Previous CloseN/A

Volume4.86K

Average Volume (3M)225.34K

Market Cap

$54.53M

Enterprise Value$60.73M

Total Cash (Recent Filing)$6.04M

Total Debt (Recent Filing)$185.00K

Price to Earnings (P/E)―

Beta-0.73

Next Earnings

Nov 18, 2025

EPS Estimate

-0.47

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.66

Shares Outstanding10,250,588

10 Day Avg. Volume624,558

30 Day Avg. Volume225,336

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.11

Enterprise Value/Revenue467.15

Enterprise Value/Gross Profit30.36K

Enterprise Value/Ebitda-4.87

Forecast

1Y Price Target

$15.00

Price Target Upside181.95% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

International ExpansionSER-252 delivery system receives market authorization in Brazil, indicating growing international recognition and potential for SER-252.

Market OpportunitiesMarket metrics appear extremely attractive with existing apomorphine drug/device combination products priced high, providing benchmarks for SER-252 pricing if approved.

Regulatory ApprovalRegulatory clearance obtained for SER-252 clinical development pathway in Parkinson's disease.

Bears Say

Clinical TrialsSER is expecting to dose the first patient in the Phase Ib trial of SER-252 in advanced Parkinson's Disease in 4Q25 following the planned IND.

CompetitionThe broadening approval footprint of enFuse bodes well for global acceptance of SER-252 in the coming years.

Existing TreatmentsCurrent formulations of apomorphine (APOKIN and ONAPGO, both marketed by Supernus Pharmaceuticals) have severe adverse events, which can hinder treatment compliance.

Serina Therapeutics News

Serina Therapeutics Stock (SER) Soars 20% on FDA Support

Serina Therapeutics stock rallied on Tuesday after the company received a positive response from the FDA. ...

7d ago

SER

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

Investors will find all of the most important stock market stories for Tuesday in our daily wrap-up. ...

7d ago

AEO

Serina Therapeutics Inc trading resumes

09:41 EDT Serina Therapeutics (SER) Inc trading resumes Published first on TheFly – the ultimate source for real-time,...

8d ago

SER

Serina Therapeutics Inc trading halted, volatility trading pause

09:36 EDT Serina Therapeutics (SER) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate...

8d ago

SER

Closing Bell Movers: Interactive Brokers up 4% on S&P500 inclusion

In the opening hour of the evening session, U.S. equity futures are up modestly, with S&P 500, Nasdaq...

8d ago

APP

Serina Therapeutics announces FDA support for SER-252 clinical study program

Serina Therapeutics (SER) announced that following a recent Type B meeting with the FDA, the FDA’s written feedback...

8d ago

SER

Serina Therapeutics Amends Bylaws for Governance Transparency

Serina Therapeutics ( ($SER) ) has issued an announcement. On August 18, 2025, Serina Therapeutics‘ Board of Directors...

11d ago

SER

Is SER a Buy, Before Earnings?

Serina Therapeutics, Inc. (SER) is scheduled to report 2nd quarter earnings on 08/08/2025. Regarding Q2 estimates, Wall Street...

28d ago

SER

Serina Therapeutics Advances SER-270 for Tardive Dyskinesia

An announcement from Serina Therapeutics ( ($SER) ) is now available. On July 29, 2025, Serina Therapeutics announced...

1M ago

SER

Serina Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Serina Therapeutics (SER) with a Buy rating and $15 price target The firm...

2M ago

SER

Serina Therapeutics Announces 2025 Annual Meeting Date

An announcement from Serina Therapeutics ( ($SER) ) is now available. Serina Therapeutics announced that its 2025 annual...

2M ago

SER

Serina Therapeutics Appoints Dr. Stephen Brannan to Board

Serina Therapeutics ( ($SER) ) has shared an update. On May 22, 2025, Serina Therapeutics announced the appointment...

3M ago

SER

Serina Therapeutics Unveils Breakthrough in LNP Technology

An update from Serina Therapeutics ( ($SER) ) is now available. On April 15, 2025, Serina Therapeutics announced...

5M ago

SER

Serina Therapeutics Secures $5M for Parkinson’s Treatment

Serina Therapeutics ( ($SER) ) has provided an update. On April 8, 2025, Serina Therapeutics announced a $5...

5M ago

SER

SER FAQ

What was Serina Therapeutics’s price range in the past 12 months?

Serina Therapeutics lowest stock price was $3.81 and its highest was $10.28 in the past 12 months.

What is Serina Therapeutics’s market cap?

Serina Therapeutics’s market cap is $54.53M.

When is Serina Therapeutics’s upcoming earnings report date?

Serina Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 76 days.

How were Serina Therapeutics’s earnings last quarter?

Serina Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.66 earnings per share for the quarter, missing the consensus estimate of -$0.425 by -$0.235.

Is Serina Therapeutics overvalued?

According to Wall Street analysts Serina Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Serina Therapeutics pay dividends?

Serina Therapeutics does not currently pay dividends.

What is Serina Therapeutics’s EPS estimate?

Serina Therapeutics’s EPS estimate is -0.47.

How many shares outstanding does Serina Therapeutics have?

Serina Therapeutics has 10,250,588 shares outstanding.

What happened to Serina Therapeutics’s price movement after its last earnings report?

Serina Therapeutics reported an EPS of -$0.66 in its last earnings report, missing expectations of -$0.425. Following the earnings report the stock price went up 7.059%.

Which hedge fund is a major shareholder of Serina Therapeutics?

Currently, no hedge funds are holding shares in SER

Serina Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

45.59%

Trailing 12-Months

Asset Growth

-16.50%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Serina Therapeutics

Serina Therapeutics (SER) is a biotechnology company focused on developing innovative therapies for unmet medical needs, particularly in the fields of oncology and autoimmune disorders. The company specializes in creating novel drug delivery systems and formulations that enhance the efficacy and safety of existing therapies. With a strong emphasis on research and development, Serina Therapeutics aims to improve patient outcomes through its proprietary technologies and a pipeline of therapeutics.

Serina Therapeutics (SER) Earnings & Revenues

Historic Earnings Reports

SER Stock 12 Month Forecast

Average Price Target

$15.00

▲(181.95% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","16":"$16","6.25":"$6.25","9.5":"$9.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,6.25,9.5,12.75,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.29,6.0369230769230775,6.783846153846154,7.530769230769231,8.277692307692309,9.024615384615386,9.771538461538462,10.51846153846154,11.265384615384615,12.012307692307694,12.75923076923077,13.506153846153847,14.253076923076925,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.29,6.0369230769230775,6.783846153846154,7.530769230769231,8.277692307692309,9.024615384615386,9.771538461538462,10.51846153846154,11.265384615384615,12.012307692307694,12.75923076923077,13.506153846153847,14.253076923076925,{"y":15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.29,6.0369230769230775,6.783846153846154,7.530769230769231,8.277692307692309,9.024615384615386,9.771538461538462,10.51846153846154,11.265384615384615,12.012307692307694,12.75923076923077,13.506153846153847,14.253076923076925,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.59,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.98,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.15,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.87,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.87,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.75,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.01,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.98,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.34,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.31,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.9,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.02,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.29,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >